Compare Stocks: SPRO, ACB, CRDL, and NMRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$3.74 +0.3%	$3.28	$2.56 ▼ $6.66	$242.51M	0.63	1.11 million shs	829,372 shs
CRDL Cardiol Therapeutics	$2.00 +0.8%	$1.57	$0.88 ▼ $2.34	$231.77M	0.79	1.63 million shs	1.24 million shs
NMRA Neumora Therapeutics	$1.04 -8.8%	$1.54	$0.83 ▼ $3.65	$195.41M	2.71	734,602 shs	1.88 million shs
SPRO Spero Therapeutics	$1.13 +0.9%	$1.36	$1.08 ▼ $3.08	$65.81M	1.49	362,433 shs	308,630 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	0.00%	-5.32%	-1.32%	+23.03%	-24.75%
CRDL Cardiol Therapeutics	0.00%	-9.32%	+16.67%	+93.69%	+83.03%
NMRA Neumora Therapeutics	0.00%	-20.61%	-39.88%	-41.57%	-36.20%
SPRO Spero Therapeutics	0.00%	-6.61%	-8.87%	-60.35%	-41.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$3.74 +0.3%	$3.28	$2.56 ▼ $6.66	$242.51M	0.63	1.11 million shs	829,372 shs
CRDL Cardiol Therapeutics	$2.00 +0.8%	$1.57	$0.88 ▼ $2.34	$231.77M	0.79	1.63 million shs	1.24 million shs
NMRA Neumora Therapeutics	$1.04 -8.8%	$1.54	$0.83 ▼ $3.65	$195.41M	2.71	734,602 shs	1.88 million shs
SPRO Spero Therapeutics	$1.13 +0.9%	$1.36	$1.08 ▼ $3.08	$65.81M	1.49	362,433 shs	308,630 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	0.00%	-5.32%	-1.32%	+23.03%	-24.75%
CRDL Cardiol Therapeutics	0.00%	-9.32%	+16.67%	+93.69%	+83.03%
NMRA Neumora Therapeutics	0.00%	-20.61%	-39.88%	-41.57%	-36.20%
SPRO Spero Therapeutics	0.00%	-6.61%	-8.87%	-60.35%	-41.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACB Aurora Cannabis	2.50	Moderate Buy	N/A	N/A
CRDL Cardiol Therapeutics	2.50	Moderate Buy	$10.00	401.25% Upside
NMRA Neumora Therapeutics	2.60	Moderate Buy	$6.57	531.87% Upside
SPRO Spero Therapeutics	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest SPRO, ACB, CRDL, and NMRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	CRDL Cardiol Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
8/17/2026	CRDL Cardiol Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $10.00
8/14/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	SPRO Spero Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/11/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
8/7/2026	ACB Aurora Cannabis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/5/2026	ACB Aurora Cannabis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/28/2026	NMRA Neumora Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	SPRO Spero Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACB Aurora Cannabis	$247.82M	0.98	$0.70 per share	5.33	$6.27 per share	0.60
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.11 per share	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$0.62 per share	N/A
SPRO Spero Therapeutics	$66.80M	0.99	$0.15 per share	7.43	$1.05 per share	1.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACB Aurora Cannabis	-$88.13M	-$1.41	N/A	62.33	N/A	-32.26%	4.37%	3.45%	11/4/2026 (Estimated)
CRDL Cardiol Therapeutics	-$24.20M	-$0.25	N/A	N/A	N/A	N/A	-180.44%	-140.28%	11/12/2026 (Estimated)
NMRA Neumora Therapeutics	-$236.93M	-$1.23	N/A	N/A	N/A	N/A	-242.28%	-131.32%	11/5/2026 (Estimated)
SPRO Spero Therapeutics	$8.57M	$0.11	10.27	N/A	N/A	24.90%	16.17%	12.57%	11/12/2026 (Estimated)

Latest SPRO, ACB, CRDL, and NMRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	NMRA Neumora Therapeutics	-$0.2401	-$0.23	+$0.0101	-$0.23	N/A	N/A
8/13/2026	Q2 2026	CRDL Cardiol Therapeutics	-$0.09	-$0.04	+$0.05	-$0.04	N/A	N/A
8/12/2026	Q2 2026	SPRO Spero Therapeutics	-$0.17	-$0.16	+$0.01	-$0.16	N/A	N/A
8/5/2026	Q1 2027	ACB Aurora Cannabis	-$0.13	$0.04	+$0.17	-$0.05	$47.45 million	$47.62 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACB Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACB Aurora Cannabis	0.03	5.36	2.80
CRDL Cardiol Therapeutics	N/A	5.55	5.55
NMRA Neumora Therapeutics	1.19	4.50	4.50
SPRO Spero Therapeutics	N/A	6.12	6.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACB Aurora Cannabis	47.63%
CRDL Cardiol Therapeutics	12.49%
NMRA Neumora Therapeutics	47.65%
SPRO Spero Therapeutics	25.60%

Insider Ownership

Company	Insider Ownership
ACB Aurora Cannabis	0.01%
CRDL Cardiol Therapeutics	5.25%
NMRA Neumora Therapeutics	26.94%
SPRO Spero Therapeutics	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACB Aurora Cannabis	1,028	64.84 million	64.84 million	Optionable
CRDL Cardiol Therapeutics	20	116.18 million	110.08 million	Not Optionable
NMRA Neumora Therapeutics	108	187.90 million	137.28 million	Optionable
SPRO Spero Therapeutics	150	58.24 million	56.55 million	Optionable

SPRO, ACB, CRDL, and NMRA Headlines

Recent News About These Companies

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 3, 2026 | globenewswire.com

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

September 2, 2026 | globenewswire.com

Spero Therapeutics stock gains on small-cap biotech interest

September 1, 2026 | ad-hoc-news.deA

Resilient Spero Therapeutics stock prepares up to $300 million shelf as Nasdaq price holds around $1.20

August 29, 2026 | ad-hoc-news.deA

Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

Alphabet Inc. Makes New Investment in Spero Therapeutics, Inc. $SPRO

August 18, 2026 | marketbeat.com

Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

August 13, 2026 | finanznachrichten.de

Spero outlines cash runway into the second half of 2029 following $105M royalty financing

August 13, 2026 | seekingalpha.com

Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript

August 12, 2026 | seekingalpha.com

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

August 12, 2026 | globenewswire.com

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 5, 2026 | globenewswire.com

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

August 4, 2026 | globenewswire.com

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

July 27, 2026 | globenewswire.com

Spero Therapeutics inks major CD40L and royalty deals

July 16, 2026 | theglobeandmail.com

Spero Therapeutics: 'Buy' On Utebzi Royalty Deal For Funding And SP001 In-Licensing

July 14, 2026 | seekingalpha.com

Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion

July 14, 2026 | reuters.com

Spero gets ex-China rights to Innovent’s antibody therapy for up to $1.1B

July 14, 2026 | msn.com

Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO)

July 14, 2026 | finance.yahoo.com

Spero Therapeutics Secures $105 Million Royalty Financing to Advance SP001 and Extend Cash Runway Through Second Half of 2029

July 14, 2026 | quiverquant.comQ

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

July 14, 2026 | globenewswire.com

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

July 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRO, ACB, CRDL, and NMRA Company Descriptions

Aurora Cannabis NASDAQ:ACB

$3.74 +0.01 (+0.27%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.75 +0.01 (+0.29%)

As of 09/11/2026 07:55 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Cardiol Therapeutics NASDAQ:CRDL

$2.00 +0.02 (+0.76%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.98 -0.01 (-0.70%)

As of 09/11/2026 07:41 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Neumora Therapeutics NASDAQ:NMRA

$1.04 -0.10 (-8.77%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.06 +0.02 (+2.40%)

As of 09/11/2026 07:56 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Spero Therapeutics NASDAQ:SPRO

$1.13 +0.01 (+0.89%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.14 +0.01 (+1.24%)

As of 09/11/2026 07:50 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPRO, ACB, CRDL, and NMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPRO, ACB, CRDL, and NMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPRO, ACB, CRDL, and NMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRO, ACB, CRDL, and NMRA Company Descriptions

Aurora Cannabis NASDAQ:ACB

Cardiol Therapeutics NASDAQ:CRDL

Neumora Therapeutics NASDAQ:NMRA

Spero Therapeutics NASDAQ:SPRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPRO, ACB, CRDL, and NMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPRO, ACB, CRDL, and NMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPRO, ACB, CRDL, and NMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRO, ACB, CRDL, and NMRA Company Descriptions

Aurora Cannabis NASDAQ:ACB

Cardiol Therapeutics NASDAQ:CRDL

Neumora Therapeutics NASDAQ:NMRA

Spero Therapeutics NASDAQ:SPRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools